Brown Brothers Harriman & CO Beam Therapeutics Inc. Transaction History

Brown Brothers Harriman & CO

  • $13.6 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$29.86 - $62.36 $8,360 - $17,460
-280 Reduced 23.55%
909 $35,000
Q1 2022

May 13, 2022
SELL
$53.73 - $82.16 $304,649 - $465,847
-5,670 Reduced 82.67%
1,189 $68,000
Q4 2021

Feb 14, 2022
BUY
$68.02 - $99.06 $316,293 - $460,629
4,650 Added 210.5%
6,859 $547,000
Q3 2021

Nov 15, 2021
BUY
$84.37 - $133.6 $186,373 - $295,122
2,209 New
2,209 $192,000

Others Institutions Holding BEAM

# of Institutions
245
Shares Held
76.7M
Call Options Held
458K
Put Options Held
202K
View Full List

About Beam Therapeutics Inc.

BEAM Quotes by TradingView
  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $2.01B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email